Brokers Set Expectations for ADCT FY2025 Earnings

ADC Therapeutics SA (NYSE:ADCT) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ADC Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings per share of ($1.66) for the year. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share.

Several other equities analysts have also commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of ADC Therapeutics in a research note on Monday, January 6th. Stephens assumed coverage on shares of ADC Therapeutics in a research note on Friday, November 8th. They issued an “overweight” rating and a $6.00 price objective for the company. Finally, Guggenheim reissued a “buy” rating and issued a $10.00 target price on shares of ADC Therapeutics in a report on Thursday, December 12th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $8.00.

ADC Therapeutics Stock Performance

ADCT opened at $1.77 on Wednesday. ADC Therapeutics has a one year low of $1.68 and a one year high of $6.04. The company has a market cap of $170.66 million, a P/E ratio of -0.74 and a beta of 1.55. The business’s 50-day simple moving average is $2.14 and its 200-day simple moving average is $2.76.

ADC Therapeutics (NYSE:ADCT) last posted its earnings results on Thursday, November 7th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.06). The company had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $18.76 million. During the same quarter in the previous year, the business earned ($0.58) earnings per share.

Insider Buying and Selling at ADC Therapeutics

In other ADC Therapeutics news, major shareholder Redmile Group, Llc bought 100,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were bought at an average price of $3.04 per share, for a total transaction of $304,000.00. Following the transaction, the insider now owns 13,145,712 shares of the company’s stock, valued at approximately $39,962,964.48. This trade represents a 0.77 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC purchased a new position in shares of ADC Therapeutics in the 2nd quarter valued at about $33,000. Intech Investment Management LLC purchased a new stake in shares of ADC Therapeutics during the 3rd quarter worth approximately $41,000. Readystate Asset Management LP purchased a new position in ADC Therapeutics in the 3rd quarter valued at approximately $54,000. SG Americas Securities LLC acquired a new position in ADC Therapeutics during the third quarter worth $84,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in ADC Therapeutics during the second quarter worth $85,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.